Navigate Global Drug Pricing with Confidence
From International Reference Pricing to US MFN policy, pharmaceutical pricing has never been more complex. At Symaptics, we built SyMAP, the AI-powered platform that cuts through the noise: transparent pricing models, revenue and patient forecasting, strategy optimisation, and explainable insights across your entire portfolio.
The SyMAP Platform
SyMAP is built to grow with your needs. Start with the full global picture (end-to-end pricing strategy with patient and revenue forecasting and an optimisation engine), or go deep on US MFN across all four pathways (GENEROUS, GLOBE, GUARD, and voluntary agreements) or on international reference pricing simulation. One modular platform, one dataset, three ways in. Explore the capabilities below.
SyMAP Global Pricing: End-to-End Pricing Strategy
SyMAP Global Pricing integrates domestic and international pricing analysis into a unified strategic framework. In today’s interconnected regulatory landscape, decisions made in one market have direct consequences in others: a discounted launch in a single country can cascade through IRP networks and reappear in US benchmarks. Our platform enables true end-to-end pricing analysis, connecting list and net prices across every market, IRP pathways, US channel exposure, and MFN benchmarks.
SyMAP MFN: Most Favored Nation Drug Pricing Toolkit
SyMAP MFN is our comprehensive toolkit for modelling Most Favored Nation (MFN) drug pricing, now across four integrated pathways. As MFN policy reshapes pharmaceutical pricing through international reference benchmarks, SyMAP MFN brings together the tools you need to analyse, simulate, and strategically respond: the CMS GENEROUS Model for Medicaid, the GLOBE Model for Medicare Part B, the GUARD Model for Medicare Part D, and (new in SyMAP 2.0) voluntary manufacturer MFN agreements.
SyMAP IRP: International Reference Pricing with AI
Our flagship tool, SyMAP IRP, is a specialised AI-powered platform for International Reference Pricing simulation and analysis. Built specifically for pharmaceutical pricing and market access teams, SyMAP IRP combines rigorous IRP modelling with explainable AI to deliver transparent, actionable insights.
Expert Analysis
MFN Policy Insights
The MFN Hub is your go-to resource for understanding Most Favored Nation drug pricing policy. Explore deep-dive analysis, strategic implications, and implementation details from the Symaptics team, covering GENEROUS, GLOBE, GUARD, and the evolving global pricing landscape.
The Art of the MFN Deal: the CEA’s $600B Report
The CEA has put a ~$600 billion price tag on MFN. The part that matters for manufacturers: the voluntary deals now reach the commercial market, and signing means weighing tariff relief against years of exposure.
Read Article →MFN and the Shift of Risk for Ex-US Markets
Although MFN policies are designed for the US, they shift pricing and policy risk onto ex-US health systems. How ex-US payers adapt will shape future access and investment.
Read Article →Redefining Ex-US Success in an MFN World
MFN pricing policies are transforming international pharmaceutical strategy. Companies must now balance local opportunities against global pricing risks, making launch timing and market selection critical.
Read Article →The End of Two Silos
Why pharmaceutical pricing is now a single global challenge. MFN creates unprecedented integration between U.S. and ex-US pricing strategies.
Read Article →GLOBE & GUARD: MFN Comes to Medicare
Comprehensive analysis of the two Medicare MFN models: 19-country reference baskets, benchmark methodologies, and key implementation differences.
Read Article →The Fine Print: Hidden Details in GLOBE & GUARD
Three overlooked provisions that could reshape your MFN strategy: PPP adjustments, benchmark lock-in, and Method II pricing dynamics.
Read Article →GENEROUS: Medicaid’s MFN Test
What CMS’s voluntary Medicaid model means for manufacturers: 8-country basket, GNUP calculations, and supplemental rebate obligations.
Read Article →Strategic Pricing Projects, Run on SyMAP
Not every pricing question arrives with a software procurement cycle attached. Where you need the answer rather than the tool, we run the project ourselves: we scope the question, build and run it in SyMAP, and hand back the analysis, the strategic interpretation and access to the app to explore the scenarios yourself.
Typical work includes Most Favored Nation impact assessments, international reference pricing simulations, global price forecasting with an optimised launch sequence, and pricing due diligence on acquisition targets.
Because the analysis is built in SyMAP rather than in a consultant’s spreadsheet, nothing is thrown away. If you licence the platform afterwards, your markets, products and every scenario we ran are already there and editable.
We also run AI training for pricing teams and build custom toolkits where a workflow genuinely belongs in Excel.
Who We Are
Chris McDonald PhD
FounderChris brings over a decade of experience in pharmaceutical pricing and market access, with a strong background in both the pharmaceutical industry and consulting. Over the past five years, he has built extensive expertise developing IRP simulation models (work that now forms the foundation of SyMAP IRP) and is actively applying this experience to the rapidly evolving MFN sector.
Specialising in intelligent AI toolkits for pharmaceutical pricing and advanced data solutions for strategic market access insight, Chris develops bespoke AI-driven solutions that address complex challenges and deliver real value. With a commitment to purposeful AI integration, these tools are tailored to meet the unique needs of the pharmaceutical industry.
Client Feedback
A fantastic AI-powered tool, tailored to our specific needs as a market access consultancy. Chris was very professional and easy to work with, developing the tool on a tight timeline and with outputs that we were really happy with. Would recommend in a heartbeat.
The bespoke services provided by Symaptics significantly improved our market access efforts.
Get in Touch
Ready to transform your pharmaceutical pricing and market access strategy? Let’s discuss how SyMAP can help your team.